Browse communities
Browse communities
Presenting a webinar?

Treating Older Adults with Generalized Anxiety Disorder

Eric Lenze, MD Associate Professor, Department of Psychiatry, Washington University School of Medicine
By 2050 there will be over 150 million older adults with anxiety disorders globally. Symptoms include sleep disturbance, interference with daily activities and distress, which can lead to medical illness such as coronary heart disease, disability, and higher levels of health care utilization.

Attendees will learn:
- How anxiety disorders in older adults differ from the disorders in younger adults.
~ They can be more detrimental to health and cognition in older adults.
~ These disorders may be more treatment-resistant, requiring aggressive treatment such as the combination of medication and psychotherapy.
- Why late-life anxiety disorders are undetected and undertreated.
- The benefits of using antidepressants and Cognitive-Behavioral Therapy as safer alternatives to treatment for these disorders in older adults.

Webinar Speaker:
Eric Lenze, MD
Associate Professor, Department of Psychiatry, Washington University School of Medicine

Dr. Lenze completed medical school and psychiatry residency at Washington University School of Medicine. He trained in a geriatric psychiatry fellowship and a clinical research fellowship at University of Pittsburgh, then joined the faculty, as part of the Advanced Center for Interventions and Services Research in Late-life mood disorders. In 2007, he returned to Washington University to focus on treatment studies in late-life anxiety disorders and depression. He carries out clinical research in disabled rehabilitating elderly populations and runs a faculty practice treating late-life anxiety disorders and depression.

Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme4
Oct 27 2010
76 mins
Treating Older Adults with Generalized Anxiety Disorder
More from this community:

Medical Research

  • Live and recorded (471)
  • Upcoming (22)
  • Date
  • Rating
  • Views
  • Join us on April 16, 2015 @ 7:00PM (EST) for Creating a Positive Patient-Provider Relationship, led by ICA Board member, Joy Selak, PhD, and her healthcare provider, Steven S. Overman, MD, MPH. Drs. Selak and Overman together wrote a book, You Don’t LOOK Sick!: Living Well with Invisible Chronic Illness, about their shared experience. This webinar will focus on how to find effective, supportive care and creating a positive patient-provider relationship.
  • Your environmental testing laboratory is facing harsher EPA emission regulations and competitive sample prices, making is essential to keep up on new technology. The BUCHI Syncore® Parallel Concentrator not only recovers > 95% of solvent but it also provides a crucial competitive advantage. Join this webinar to learn how today’s top environmental testing laboratories are staying ahead of their competition with the implementation of the Syncore® Analyst.
  • Regardless of the colour of the next UK government that emerges as a result of the May election, the £30-£50bn NHS budget chasm is the abyss that all the parties fear in respect of its thereat to quality health service delivery and re-election.

    With political backs to the abyss, no hostages will be taken. It is not unrealistic to expect a well co-ordinated and concerted offence by politicians and patient organisations alike on industry pricing of innovative speciality and rare diseases medicines:

    With this scenario in mind pharmaphorum is once again working with IMS Health to bring you expert insight into what this means for the UK health system and more specifically market access for specialist treatments in the post-election environment.

    Angela McFarlane, Senior principal IMS Health Local Market Access, Anthony Grosso, Principal Pharmacist at the National Hospital for Neurology and Neurosurgery and Sheela Upadhyaya, previously a NHS Senior Manager with over 17 years of experience in the delivery of services and in commissioning of highly specialised services for rare and ultra rare conditions, combine with pharmaphorum's Paul Tunnah to deliver an accurate analysis and frontline insight as to the already complex roadmap for access is about to change again.

    This one hour event will include analysis of informed predictions which include:

    The NICE HTA criteria will get tougher post end to end review (IMMTreV)
    NICE and the NHS England will join forces to streamline access pre/post NICE
    Risk at local level will be shifted to Providers under the new marginal tariff arrangements; which could indeed see a close to the CDF as the PbR excluded drugs list becomes a thing of a glorious past
    Provider baselines will take the strain of innovation - the tough decisions will be softened by a drive to really accelerate uptake of NICE approved medicines

    How can industry prepare for these changes in what is already a tough and complex environment?
  • Although there are many techniques to study epigenetic marks such as DNA- and histone-methylation, on a genomic scale, there exists a need in the field to visualize these epigenetic marks at a single genomic locus in individual cells. Such an application requires a highly sensitive detection method. With this aim, a protocol was developed to perform in-situ hybridization followed by proximity ligation assay (a.k.a. Duolink®) and cell imaging to visualize DNA-methylation (5meC) on the SEPTIN9 promoter. SEPTIN9 promoter methylation is a known biomarker for colon cancer. After optimizing cross-linking, cell permeabilization and chromatin accessibility, the genomic specificity was ascertained by hybridizing with a pool of biotinylated-oligo probes that target the CpG islands in the human SEPTIN9 promoter. The Duolink assay was performed using anti-biotin and anti-5meC antibodies, corresponding proximity ligation assay probes, and Far Red detection reagents.
    Imaging by fluorescent microscopy revealed two red punctate spots in metastatic prostate cancer DU145 cells (diploid for chromosome 17 – location of SEPTIN9 gene) and three red spots in colon cancer SW480 cells (triploid for Chr17). No signal was observed in normal cells (BJ) or with non-specific oligo probes (LacZ). A decrease in Duolink signal was observed when the DU145 cells were treated with 5-AzaC, a drug known to block DNA-methylation. This proof of concept study will be extended to frozen and formalin fixed paraffin embedded human cancer tissue samples.
    Fluorescent imaging data will also be presented from a Duolink assay to monitor the interaction of EZH2 histone methyltransferase with the H3K27me3 epigenetic mark in prostate cancer (DU145) cells. Reduction in the Duolink signal demonstrated inhibition of EZH2 activity by the small molecule inhibitors SAHA and GSK343.
  • Although there are many techniques to study epigenetic marks such as DNA- and histone-methylation, on a genomic scale, there exists a need in the field to visualize these epigenetic marks at a single genomic locus in individual cells. Such an application requires a highly sensitive detection method. With this aim, a protocol was developed to perform in-situ hybridization followed by proximity ligation assay (a.k.a. Duolink®) and cell imaging to visualize DNA-methylation (5meC) on the SEPTIN9 promoter. SEPTIN9 promoter methylation is a known biomarker for colon cancer. After optimizing cross-linking, cell permeabilization and chromatin accessibility, the genomic specificity was ascertained by hybridizing with a pool of biotinylated-oligo probes that target the CpG islands in the human SEPTIN9 promoter. The Duolink assay was performed using anti-biotin and anti-5meC antibodies, corresponding proximity ligation assay probes, and Far Red detection reagents.
    Imaging by fluorescent microscopy revealed two red punctate spots in metastatic prostate cancer DU145 cells (diploid for chromosome 17 – location of SEPTIN9 gene) and three red spots in colon cancer SW480 cells (triploid for Chr17). No signal was observed in normal cells (BJ) or with non-specific oligo probes (LacZ). A decrease in Duolink signal was observed when the DU145 cells were treated with 5-AzaC, a drug known to block DNA-methylation. This proof of concept study will be extended to frozen and formalin fixed paraffin embedded human cancer tissue samples.
    Fluorescent imaging data will also be presented from a Duolink assay to monitor the interaction of EZH2 histone methyltransferase with the H3K27me3 epigenetic mark in prostate cancer (DU145) cells. Reduction in the Duolink signal demonstrated inhibition of EZH2 activity by the small molecule inhibitors SAHA and GSK343.
  • How do ischemia and fixation impact the quality of your assay results and information transfer? Garbage in! Garbage out! Join Geoffrey Baird MD, PhD and David Chafin, PhD at 9 AM Mountain Time, March 31, 2015, who will discuss the impact of ischemia and fixation on assay results, information transfer and some novel approaches to address these important factors. Dr. Baird is an Assistant Professor of Laboratory Medicine and an Adjunct Assistant Professor of Pathology at the University of Washington. Dr. Chafin is a Principle Scientist, Technology and Applied Research at Ventana Medical Systems Inc.
  • C-H functionalization is a powerful addition to the toolbox of the medicinal chemist. Modern C-H functionalization techniques hold the potential to enable the rapid exploration of structure activity relationships (SAR), the generation of oxidized metabolites, the blocking of metabolic hot spots and the preparation of biological probes. This presentation will describe a variety of high-value C-H functionalization chemistries, developed in house and in collaboration with academic groups, and give examples of how these technologies have been deployed successfully to impact drug discovery programs.
  • How can ischemia impact your assay results? Watch this video and see...
  • This webinar will discuss the evolving role of Cell Lines and Cell Culture and their usefulness as models of physiological function and disease. The webinar will review the depth, breadth and best use of currently available Cell Lines. The role played by Cell Lines in ensuring that the output of future research continues to be valid and credible will also be evaluated. This is the first of a three part webinar series focused on delivering a broad picture of the role of cell lines as models in scientific research, the various strategies and approaches available.
  • Abstract:
    There is a great interest in application of human mesenchymal stem cells (hMSCs) in cell therapy and tissue engineering due to their self-renewal, multi-lineage differentiation, immunomodulation, and trophic potential. One of the challenges faced in the clinical application of hMSCs is the need for efficient expansion of these cells in vitro without altering their capacity. Serum-free mammalian cell culture media, in particular, require optimization of the expansion protocols. Even subtle changes in routine handling can have a significant impact on the cells’ potential.

    This seminar will cover the variables that can influence the desired regenerative and differentiation properties including medium selection, vessel surface treatment, impact of the cell source, and seeding density. We will also discuss how users can select the correct conditions for optimized growth and functionality.

    Speaker Biography:
    Brian Posey is a Product Development Manager for cell culture media at Corning Life Sciences. Brian has over 10 years experience in cell biology and industrial scale cGMP manufacturing of both liquid and powder cell culture media. Since joining Corning in 2012, Brian has lead numerous innovative technology projects for the media business ranging from customer technology transfer for production scale-up to developing new serum-free media for industrial and stem cell lines.
  • Channel
  • Channel profile
  • GAD and Substance Abuse Recorded: Nov 23 2010 70 mins
    Dr. Susan Sonne, Associate Professor of Psychiatry and Pharmacy at the Medical University of South Carolina
    Substance use disorders commonly co-occur with anxiety disorders. Diagnosing anxiety disorders in the face of active substance use and withdrawal can be very challenging due to the significant symptom overlap. This symptom overlap often leads to delayed or inadequate treatment. When treating individuals with generalized anxiety disorder and a substance use disorder, benzodiazepines should be avoided. Selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors are FDA-approved to treat GAD and are fairly safe in substance users. Other non-FDA approved medications will also be discussed.

    During this webinar, attendees will learn:

    -What symptoms of anxiety overlap with substance use and withdrawal

    - How to diagnose anxiety disorders in the face of substance use

    -Why substance abuse and anxiety disorders co-occur so frequently

    -How to treat individuals with anxiety disorders and comorbid substance abuse

    Dr. Susan Sonne is active in research and teaching as Associate Professor of Psychiatry and Pharmacy at the Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, Clinical Neuroscience Division.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme6
  • GAD and Cormorbidity: Impact on Patient Health Recorded: Nov 9 2010 66 mins
    Dr. Naomi M. Simon, Associate Director of the Center for Anxiety and Traumatic Stress Disorders
    Generalized Anxiety Disorder (GAD) is common, chronic, and associated with substantial impairment in function and quality of life. GAD commonly occurs comorbid with mood disorders and anxiety disorders. GAD comorbidity has been clearly linked to additive worsening of outcomes and function in both Major Depressive Disorder and in Bipolar Disorder. This presentation will provide an update on current understandings about the incidence and nature of GAD and comorbid disorders, and their impact on patient health.

    During this webinar attendees will:

    1) Understand the overlap of Generalized Anxiety Disorder (GAD) with mood disorders

    2) Understand the impact of GAD comorbidity on severity of illness including suicidality, quality of life and functioning in individuals with GAD

    3) Learn about the need to address GAD and its comorbidities to optimally improve patient health

    Naomi Michele Simon, M.D., M.Sc.

    Dr. Naomi M. Simon is Associate Director of the Center for Anxiety and Traumatic Stress Disorders and Director of the recently established Complicated Grief Program at Massachusetts General Hospital, and is Associate Professor of Psychiatry, Harvard Medical School.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/ADAA_CME5
  • Treating Older Adults with Generalized Anxiety Disorder Recorded: Oct 27 2010 76 mins
    Eric Lenze, MD Associate Professor, Department of Psychiatry, Washington University School of Medicine
    By 2050 there will be over 150 million older adults with anxiety disorders globally. Symptoms include sleep disturbance, interference with daily activities and distress, which can lead to medical illness such as coronary heart disease, disability, and higher levels of health care utilization.

    Attendees will learn:
    - How anxiety disorders in older adults differ from the disorders in younger adults.
    ~ They can be more detrimental to health and cognition in older adults.
    ~ These disorders may be more treatment-resistant, requiring aggressive treatment such as the combination of medication and psychotherapy.
    - Why late-life anxiety disorders are undetected and undertreated.
    - The benefits of using antidepressants and Cognitive-Behavioral Therapy as safer alternatives to treatment for these disorders in older adults.

    Webinar Speaker:
    Eric Lenze, MD
    Associate Professor, Department of Psychiatry, Washington University School of Medicine

    Dr. Lenze completed medical school and psychiatry residency at Washington University School of Medicine. He trained in a geriatric psychiatry fellowship and a clinical research fellowship at University of Pittsburgh, then joined the faculty, as part of the Advanced Center for Interventions and Services Research in Late-life mood disorders. In 2007, he returned to Washington University to focus on treatment studies in late-life anxiety disorders and depression. He carries out clinical research in disabled rehabilitating elderly populations and runs a faculty practice treating late-life anxiety disorders and depression.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme4
  • Treating GAD in Primary Care Settings Recorded: Oct 13 2010 78 mins
    Larry Culpepper, MD, MPH Professor and Chairman, Department of Family Medicine, Boston University
    Attendees will:
    - recognize symptoms of Generalized Anxiety Disorder in primary care patients
    - use current pharmacological and psychotherapeutic treatments to develop a management plan
    - assess different treatments for comorbid GAD and refractory cases

    Webinar Speaker:
    Larry Culpepper, MD, MPH
    Professor of Family Medicine and Chairman, Department of Family Medicine, Boston University

    Dr. Culpepper has conducted federally funded studies of depression and anxiety, otitis media, and school-based and community interventions to improve pregnancy outcomes and to prevent teen pregnancies. He currently is the principal investigator of an AHRQ funded developmental center for patient safety research devoted to the study of problems affecting low income and minority vulnerable populations in ambulatory care settings, and co-investigator of the Primary Care Anxiety Project, a study of the course of anxiety disorders in primary care settings.

    Dr. Culpepper also is Chief of Family Practice at Boston Medical Center. He received his MD degree from Baylor College of Medicine and his MPH degree from Boston University.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme3
  • Psychosocial Treatments for Generalized Anxiety Disorder Recorded: Oct 8 2010 72 mins
    Douglas Mennin, PhD, Director of the Yale Anxiety and Mood Services Clinic
    Attendees will:
    - Discuss current evidence-based psychotherapeutic treatments for adults with generalized anxiety disorder.
    - Identify characteristics of generalized anxiety disorder.
    - Design a psychosocial treatment plan with patients with GAD.

    Webinar Speaker:
    Douglas Mennin, PhD
    Associate Professor of Psychology, Yale University and Director of the Yale Anxiety and Mood Services Clinic

    Dr. Mennin has focused his research program on understanding and treating chronic and reoccurring bouts of anxiety and mood disorders, particularly worry, stress, and depression. Our understanding of problems related to anxiety and depression has increased exponentially in the past twenty years. Advances in biological and behavioral technologies has helped us shine light on how everyday feelings such as fear and sadness can, in some individuals, translate into emotional disorder.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/ADAA_CME2
  • Understanding & Treating Generalized Anxiety Disorder Recorded: Sep 21 2010 77 mins
    Mark Pollack, MD, Director, Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital
    Attendees will:
    - discuss the neurobiology of GAD
    - recognize symptoms and diagnose individuals with generalized anxiety disorder
    - plan evidence-based treatment for individuals with GAD and gad and comorbid disorders including depression, sleep disorders, cardiac illnesses and IBS.

    Webinar speaker:
    Mark Pollack, MD, Director, Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital
    Professor of Psychiatry, Harvard Medical School

    Dr. Pollack’s areas of clinical and research interest include the acute and long-term course, pathophysiology, and treatment of patients with anxiety disorders and associated comorbidities, development of novel pharmacologic agents for mood and anxiety disorders, uses of combined cognitive-behavioral and pharmacologic therapies for treatment refractory patients, presentation and treatment of anxiety in the medical setting, and the pathophysiology and treatment of substance abuse.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/ADAA_CME1
Anxiety disorders are real, serious & treatable
Anxiety disorders are real, serious & treatable

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Treating Older Adults with Generalized Anxiety Disorder
  • Live at: Oct 27 2010 5:00 pm
  • Presented by: Eric Lenze, MD Associate Professor, Department of Psychiatry, Washington University School of Medicine
  • From:
Your email has been sent.
or close
You must be logged in to email this